Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels.
Molly Johannessen, Dominique Fontanilla, Timur Mavlyutov, Arnold E Ruoho, Meyer B Jackson
Index: Am. J. Physiol. Cell Physiol. 300(2) , C328-37, (2011)
Full Text: HTML
Abstract
σ-Receptors are integral membrane proteins that have been implicated in a number of biological functions, many of which involve the modulation of ion channels. A wide range of synthetic ligands activate σ-receptors, but endogenous σ-receptor ligands have proven elusive. One endogenous ligand, dimethyltryptamine (DMT), has been shown to act as a σ-receptor agonist. Progesterone and other steroids bind σ-receptors, but the functional consequences of these interactions are unclear. Here we investigated progesterone binding to σ(1)- and σ(2)-receptors and evaluated its effect on σ-receptor-mediated modulation of voltage-gated Na(+) channels. Progesterone binds both σ-receptor subtypes in liver membranes with comparable affinities and blocks photolabeling of both subtypes in human embryonic kidney 293 cells that stably express the human cardiac Na(+) channel Na(v)1.5. Patch-clamp recording in this cell line tested Na(+) current modulation by the σ-receptor ligands ditolylguanidine, PB28, (+)SKF10047, and DMT. Progesterone inhibited the action of these ligands to varying degrees, and some of these actions were reduced by σ(1)-receptor knockdown with small interfering RNA. Progesterone inhibition of channel modulation by drugs was consistent with stronger antagonism of σ(2)-receptors. By contrast, progesterone inhibition of channel modulation by DMT was consistent with stronger antagonism of σ(1)-receptors. Progesterone binding to σ-receptors blocks σ-receptor-mediated modulation of a voltage-gated ion channel, and this novel membrane action of progesterone may be relevant to changes in brain and cardiovascular function during endocrine transitions.
Related Compounds
Related Articles:
Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.
2016-01-22
[Toxicol. Lett. 241 , 82-94, (2015)]
2014-04-01
[Biochem. Pharmacol. 88(3) , 393-401, (2014)]
2012-01-01
[Drug Test. Anal. 4(7-8) , 610-6, (2012)]
2011-09-01
[Biomed. Chromatogr. 25(9) , 970-84, (2011)]
2009-12-01
[J. Neural Transm. Gen. Sect. 116(12) , 1591-9, (2009)]